HPLC Analysis of the Major Urinary Metabolite of Flurazepam
Pharmacokinetic parameters of a drug are commonly evaluated by the determination of unchanged drug in blood or plasma. An acceptable alternative , especially if a non-invasive method is desired, is to use urinary excretion data for either the unchanged drug or a major metabolite. If the latter represents a significant percentage of the administered dose, its quantitation places fewer constraints on the sensitivity required of the analytical procedure, and on the sample preparation and ‘clean-up’ required prior to analysis. HPLC, either normal-phase (NP) or reverse-phase (RP), is ideally suited to this type of determination . RP conditions have now been developed.
KeywordsUnchanged Drug Control Urine Differential Pulse Polarography Urinary Excretion Data Major Urinary Metabolite
Unable to display preview. Download preview PDF.
- 1.Federal Register (1977) 42 (5) , 1624–1653Google Scholar
- 2.de Silva, J.A.F. (1981) in Trace-Organic Sample Handling (Vol. 11, this series; Reid, E., ed.) , Horwood, Chichester, pp. 192–204.Google Scholar
- 6.Peat, M.A. & Kopjak, L. (1979)J. Forens Sci. 24, 46–54.Google Scholar
- 7.de Silva, J.A.F., Bekersky, I. & Puglisi, C.V. (1974) J. Pharm.Sci. 63, 1837–1841.Google Scholar
- 12.Brooks, M.A. (1980) in Electroanalysis in Hygiene, Environmental, Clinical and Pharmaceutical Chemistry (Franklin-Smyth, W., ed.) , Elsevier, Amsterdam, pp. 287–298.Google Scholar